Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/clarification-chinese-version-only
https://www.med.cuhk.edu.hk/press-releases/clarification-chinese-version-only

Clarification -- 聲稱為莫樹錦教授署名文章証實為假冒 (Chinese Version Only)

香港中文大學醫學院澄清,近日網上及流動應用程式流傳,聲稱由莫樹錦教授撰寫、題為《給撤回條例後仲盲撑暴徒的人》的文章,並非出於莫教授的手筆。莫樹錦教授已証實他從沒有發表過有關文章,希望各界明察,勿再誤傳。

 

香港中文大學醫學院

 

網上流傳之文字如下:

 

-------------

 

莫樹錦醫生的敢言
 

給撤回條例後仲盲撐暴徒的人:

 

如果有天,你坐車去處理一件好重要既事,或者見工,或者睇病,或者見親人最後一面,但被暴徒堵路,最後遲大到,甚至去唔到。

 

《不要憤怒,是你支持的》

 

 

如果有天,你的子女因為你不答應佢既訴求,就唔比你返工,打爛你家中傢俬電器玻璃窗等死物,仲在屋企門口縱火。

 

《不要嗟嘆,是你教育的》

 

如果有天,你趕住要搭飛機去外國工作、旅行或者探屋企人,但機場被堵塞佔領,暴徒還阻你上機,點解釋請求都只係涼薄地恥笑你。

 

《不要徬徨,是你助長的》

 

 

如果有天,你在港鐵上趕往辦要事,但車門開了又關關了又開總不開車,前面鐵路還有車出軌,廣播卻壞了,站也關閉了,燃燒彈由地面不停掟落月台,電纜上還掛著架單車。

 

《不要著急,是你慫恿的》

 

 

如果有天,你只是在拍照,但卻被暴徒圍繞,話要檢查你拍咗咩相片,唔俾就搶你手機,你保護自己財物,佢哋就當你係死物,打到你危殆仲被所謂醫護虐待多幾吓。

 

《不要害怕,是你默許的》

 

 

如果有天,社會不安,治安敗壞,經濟不景,外商不敢投資,遊客不敢訪港,結果你公司倒閉,或者你被公司栽員,你的子女大學一畢業就失業。

 

《不要哀傷,是你造成的》

 

 

如果有天,香港基建停頓,經濟發展被攬炒成功,不進反而急退,眼白白睇住深圳超越香港成為大灣區龍頭金融中心,你的仔女繼續上樓唔到,又上唔到車,日日失業在家鬧你癈老阻住地球轉。

 

《不要慨嘆,是你縱容的》

 

 

撤回條例後仲盲撐暴徒的人:

 

《將來不要後悔,全都是你們一手造成的》

 

不要跟我說不會,這些事其實已經在發生了。

More Press Releases

Clarification from CU Medicine

Clarification from CU Medicine

Response
Clarification from CU Medicine

Clarification from CU Medicine

Response
Clarification from CU Medicine

Clarification from CU Medicine

Response
Clarification -- 中大醫學院澄清啟事 (Chinese Version Only)

Clarification -- 中大醫學院澄清啟事 (Chinese Version Only)

Response
International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

International lung cancer study involving CU Medicine reveals that combination of immune drugs and chemotherapy represents new treatment regime for metastatic NSCLC patients

Research
中大醫學院就行政長官今日(10月19日)發表2022施政報告的回應 (Chinese Version Only)

中大醫學院就行政長官今日(10月19日)發表2022施政報告的回應 (Chinese Version Only)

Response
CUHK co-leads global lung cancer study  Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

CUHK co-leads global lung cancer study Supporting lorlatinib as first-line treatment option for ALK-positive advanced NSCLC patients

Research
CU Medicine collaborates with South Korean institutes to develop  an AI-powered analytic tool for lung cancer immunotherapy

CU Medicine collaborates with South Korean institutes to develop an AI-powered analytic tool for lung cancer immunotherapy

Research
中大醫學院就2022-23財政預算案的回應 (Chinese Version Only)

中大醫學院就2022-23財政預算案的回應 (Chinese Version Only)

Response
Professor Tony Mok Recognised as a Giant of Cancer Care  for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Professor Tony Mok Recognised as a Giant of Cancer Care for His Remarkable Contribution in Advancing Global Healthcare in Lung Cancer

Awards and honors
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
Two CUHK Research Projects Receive State Science and Technology Awards

Two CUHK Research Projects Receive State Science and Technology Awards

Awards and honors
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

CUHK Leads a Multinational Study that Finds New Treatment Paradigm of Mutated Lung Cancer

Research
CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

CUHK Joint Research Sets a New Global Direction for Lung Cancer Treatment Molecular Targeted Therapy Proved more Effective in Treating Patients with ALK-Positive Lung Cancer

Research
Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Inaugural Lecture of Li Shu Fan Medical Foundation Professorship in Clinical Oncology by Prof. Tony Mok 'Declaration of War Against Lung Cancer'

Symposium

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.